An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond

References

• Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):197.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963–967.
   PubMed Web of Science ®Google Scholar
• Daccord C, Maher TM. Recent advances in understanding idiopathic pulmonary fibrosis. F1000Res. 2016;5:1046. doi: 10.12688/f1000research.8209.1
   Google Scholar
• Lederer DJ, Martinez FJ, Longo DL. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811–1823. doi: 10.1056/NEJMra1705751
   PubMed Web of Science ®Google Scholar
• Confalonieri P, Volpe MC, Jacob J, et al. Regeneration or Repair? The role of alveolar epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Cells. 2022;11(13). doi: 10.3390/cells11132095
   PubMed Web of Science ®Google Scholar
• Kathiriya JJ, Wang C, Zhou M, et al. Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5(+) basal cells. Nat Cell Biol. 2022;24(1):10–23.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Kropski JA, Jones MG, et al. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Ther. 2021;222:107798. doi: 10.1016/j.pharmthera.2020.107798
   PubMed Web of Science ®Google Scholar
• Luppi F, Kalluri M, Faverio P, et al. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir Res. 2021;22(1):109.
   PubMed Web of Science ®Google Scholar
• Peljto AL, Blumhagen RZ, Walts AD, et al. Idiopathic pulmonary fibrosis is associated with common genetic variants and limited rare variants. Am J Respir Crit Care Med. 2023;207(9):1194–1202.
   PubMed Web of Science ®Google Scholar
• Grimminger F, Günther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1426–1433. doi: 10.1183/09031936.00149614
   PubMed Web of Science ®Google Scholar
• Bergeron A, Soler P, Kambouchner M, et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur Respir J. 2003;22(1):69–76.
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med. 2014;189(10):1161–1172. doi: 10.1164/rccm.201312-2221PP
   PubMed Web of Science ®Google Scholar
• Wuyts WA, Agostini C, Antoniou KM, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J. 2013;41(5):1207–1218.
   PubMed Web of Science ®Google Scholar
• Raghu G, Anstrom KJ, King TEJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Pardo A, Selman M. Lung fibroblasts, aging, and idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2016;13(Suppl 5):S417–S421. doi: 10.1513/AnnalsATS.201605-341AW
   PubMed Web of Science ®Google Scholar
• Carlos WG, Strek ME, Wang TS, et al. Treatment of idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2016;13(1):115–117.
   PubMed Web of Science ®Google Scholar
• Petnak T, Lertjitbanjong P, Thongprayoon C, et al. Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest. 2021;160(5):1751–1763.
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. doi: 10.1056/NEJMoa1402584
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–1087.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir med. 2016;113:74–79. doi: 10.1016/j.rmed.2016.02.001
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (London, England). 2011;377(9779):1760–1769. doi: 10.1016/S0140-6736(11)60405-4
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47.
   PubMed Web of Science ®Google Scholar
• Pan L, Cheng Y, Yang W, et al. Nintedanib Ameliorates bleomycin-induced pulmonary fibrosis, inflammation, apoptosis, and oxidative stress by modulating PI3K/Akt/mTOR Pathway in mice. Inflammation. 2023 May;46(4):1531–1542. Published online. doi: 10.1007/s10753-023-01825-2
   PubMed Web of Science ®Google Scholar
• Lasky JA, Criner GJ, Lazarus HM, et al. Safety of nintedanib in patients with idiopathic pulmonary fibrosis: global pharmacovigilance data. Adv Ther. 2020;37(10):4209–4219.
   PubMed Web of Science ®Google Scholar
• Podolanczuk AJ, Cottin V. A narrative review of real-world data on the safety of nintedanib in patients with idiopathic pulmonary fibrosis. Adv Ther. 2023;40(5):2038–2050. doi: 10.1007/s12325-023-02454-9
   PubMedGoogle Scholar
• Galli JA, Pandya A, Vega-Olivo M, et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology. 2017;22(6):1171–1178.
   PubMed Web of Science ®Google Scholar
• Harari S, Pesci A, Albera C, et al. Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study. Respiration. 2022;101(6):577–584.
   PubMedGoogle Scholar
• Gori S, Inno A, Belluomini L, et al. Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Crit Rev Oncol Hematol. 2019;143:139–147. doi: 10.1016/j.critrevonc.2019.09.003
   PubMed Web of Science ®Google Scholar
• Secombe KR, Van Sebille YZA, Mayo BJ, et al. Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome. Integr Cancer Ther. 2020;19:1534735420928493. doi: 10.1177/1534735420928493
   Web of Science ®Google Scholar
• Wind S, Schmid U, Freiwald M, et al. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019;58(9):1131–1147.
   PubMed Web of Science ®Google Scholar
• Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol. 2020;62(4):413–422. doi: 10.1165/rcmb.2019-0328TR
   PubMed Web of Science ®Google Scholar
• King TEJ, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi: 10.1056/NEJMoa1402582
   PubMed Web of Science ®Google Scholar
• Ley B, Swigris J, Day B-M, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196(6):756–761.
   PubMed Web of Science ®Google Scholar
• Vancheri C, Sebastiani A, Tomassetti S, et al. Pirfenidone in real life: a retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Respir med. 2019;156:78–84. doi: 10.1016/j.rmed.2019.08.006
   PubMed Web of Science ®Google Scholar
• Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol. 1999;57(9):965–973. doi: 10.1016/S0006-2952(98)00331-1
   PubMed Web of Science ®Google Scholar
• Hertz AL, Bender AT, Smith KC, et al. Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages. Proc Natl Acad Sci U S A. 2009;106(51):21978–21983.
   PubMed Web of Science ®Google Scholar
• Matsuhira T, Nishiyama O, Tabata Y, et al. A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung. Eur J Pharmacol. 2020;885:173508. doi: 10.1016/j.ejphar.2020.173508
   PubMed Web of Science ®Google Scholar
• Selige J, Hatzelmann A, Dunkern T. The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion. J Cell Physiol. 2011;226(8):1970–1980. doi: 10.1002/jcp.22529
   PubMed Web of Science ®Google Scholar
• Ti H, Zhou Y, Liang X, et al. Targeted treatments for chronic obstructive pulmonary disease (COPD) using low-molecular-weight drugs (LMWDs). J Med Chem. 2019;62(13):5944–5978.
   PubMed Web of Science ®Google Scholar
• Murray LA, Argentieri RL, Farrell FX, et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol. 2008;40(10):2174–2182.
   PubMed Web of Science ®Google Scholar
• Kolb M, Bonniaud P, Galt T, et al. Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of “fibrosis-prone” and “fibrosis-resistant” mouse strains. Am J Respir Cell Mol Biol. 2002;27(2):141–150.
   PubMed Web of Science ®Google Scholar
• Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997;100(4):768–776.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Azuma A, Cottin V, et al. Trial of a Preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med. 2022;386(23):2178–2187.
   PubMed Web of Science ®Google Scholar
• Lipson KE, Wong C, Teng Y, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S24.
   PubMedGoogle Scholar
• Raghu G, Scholand MB, de Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47(5):1481–1491.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25–33. doi: 10.1016/S2213-2600(19)30262-0
   PubMed Web of Science ®Google Scholar
• Gagnon L, Leduc M, Thibodeau J-F, et al. A newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84. Am J Pathol. 2018;188(5):1132–1148.
   PubMed Web of Science ®Google Scholar
• Labéguère F, Dupont S, Alvey L, et al. Discovery of 9-cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a unique GPR84 negative allosteric modulator undergoing evaluation in a phase II clinical trial. J Med Chem. 2020;63(22):13526–13545.
   PubMed Web of Science ®Google Scholar
• Saniere L, Marsais F, Jagerschmidt C, et al. Characterization of GLPG1205 in mouse fibrosis models: a potent and selective antagonist of GPR84 for treatment of idiopathic pulmonary fibrosis. In: A19. LESS IDIOPATHIC: STRUCTURAL AND FUNCTIONAL ABNORMALITIES IN IPF. American Thoracic Society International Conference Abstracts. American Thoracic Society; Dallas, Texas. 2019. p. A1046–A1046.
   Google Scholar
• P612. Human safety, pharmacokinetics and pharmacodynamics of the GPR84 antagonist GLPG1205, a potential new approach to treat IBD. J Crohn’s Colitis. 2015;9(suppl_1):S387–S387. doi: 10.1093/ecco-jcc/jju027.730
   Google Scholar
• Strambu IR, Seemayer CA, Fagard L-C, et al. GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial. Eur Respir J. 2023;61(3):2201794. doi: 10.1183/13993003.01794-2022
   PubMed Web of Science ®Google Scholar
• Naik-Mathuria B, Pilling D, Crawford JR, et al. Serum amyloid P inhibits dermal wound healing. Wound Repair Regen Off Publ Wound Heal Soc [And] Eur Tissue Repair Soc. 2008;16(2):266–273.
   PubMed Web of Science ®Google Scholar
• Pilling D, Buckley CD, Salmon M, et al. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol. 2003;171(10):5537–5546.
   PubMed Web of Science ®Google Scholar
• Pilling D, Gomer RH. The development of serum amyloid P as a possible therapeutic. Front Immunol. 2018;9:2328. doi: 10.3389/fimmu.2018.02328
   PubMed Web of Science ®Google Scholar
• Murray LA, Chen Q, Kramer MS, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol. 2011;43(1):154–162.
   PubMed Web of Science ®Google Scholar
• Raghu G, van den Blink B, Hamblin MJ, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA. 2018;319(22):2299–2307.
   PubMed Web of Science ®Google Scholar
• Raghu G, Hamblin MJ, Brown AW, et al. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respir Res. 2022;23(1):129.
   PubMed Web of Science ®Google Scholar
• Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177(1):56–65.
   PubMed Web of Science ®Google Scholar
• Raghu G, Mouded M, Chambers DC, et al. A phase IIb randomized clinical study of an anti-α(v)β(6) monoclonal antibody in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2022;206(9):1128–1139.
   PubMed Web of Science ®Google Scholar
• Puthawala K, Hadjiangelis N, Jacoby SC, et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med. 2008;177(1):82–90.
   PubMed Web of Science ®Google Scholar
• Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96(3):319–328.
   PubMed Web of Science ®Google Scholar
• François A, Gombault A, Villeret B, et al. B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. J Autoimmun. 2015;56:1–11. doi: 10.1016/j.jaut.2014.08.003
   PubMed Web of Science ®Google Scholar
• Rivera R, Chun J. Biological effects of lysophospholipids. Rev Physiol Biochem Pharmacol. 2008;160:25–46.
   PubMed Web of Science ®Google Scholar
• Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14(1):45–54.
   PubMed Web of Science ®Google Scholar
• Montesi SB, Mathai SK, Brenner LN, et al. Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis. BMC Pulm Med. 2014;14(1):5.
   PubMedGoogle Scholar
• Shea BS, Tager AM. Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis. Proc Am Thorac Soc. 2012;9(3):102–110. doi: 10.1513/pats.201201-005AW
   PubMedGoogle Scholar
• Decaris ML, Schaub JR, Chen C, et al. Dual inhibition of α(v)β(6) and α(v)β(1) reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res. 2021;22(1):265. doi: 10.1186/s12931-021-01863-0
   PubMed Web of Science ®Google Scholar
• Partridge EA, Le Roy C, Di Guglielmo GM, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 2004;306(5693):120–124.
   PubMed Web of Science ®Google Scholar
• Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537–546.
   PubMed Web of Science ®Google Scholar
• Chen W-S, Cao Z, Leffler H, et al. Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis. Invest Ophthalmol Vis Sci. 2017;58(1):9–20.
   PubMed Web of Science ®Google Scholar
• Jastrzębski K, Zdżalik-Bielecka D, Mamińska A, et al. Multiple routes of endocytic internalization of PDGFRβ contribute to PDGF-induced STAT3 signaling. J Cell Sci. 2017;130(3):577–589.
   PubMed Web of Science ®Google Scholar
• Nishi Y, Sano H, Kawashima T, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int Off J Japanese Soc Allergol. 2007;56(1):57–65.
   Google Scholar
• Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172(2):288–298.
   PubMed Web of Science ®Google Scholar
• MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008;180(4):2650–2658.
   PubMed Web of Science ®Google Scholar
• Parmar NR, Mackinnon AC, Zetterberg F, et al. Role of galectin-3 in idiopathic pulmonary fibrosis development. In: C62. FIBROBLAST BIOLOGY. American Thoracic Society International Conference Abstracts; Dallas, Texas. American Thoracic Society; 2019. p. A5328–A5328.
   Google Scholar
• Hirani N, MacKinnon AC, Nicol L, et al. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021;57(5):2002559. doi: 10.1183/13993003.02559-2020
   PubMed Web of Science ®Google Scholar
• Hirani N, MacKinnon AC, Nicol L, et al. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021;57(4):2002559. Eur Respir J. 2022;59. doi: 10.1183/13993003.02559-2020
   PubMedGoogle Scholar
• Yamada S, Imura Y, Nakai T, et al. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma. BMC Cancer. 2017;17(1):334.
   PubMedGoogle Scholar
• Fujita H, Gomori A, Fujioka Y, et al. High potency VEGFRs/MET/FMS triple blockade by TAS-115 concomitantly suppresses tumor progression and bone destruction in tumor-induced bone disease model with lung carcinoma cells. PLoS One. 2016;11(10):e0164830.
   PubMed Web of Science ®Google Scholar
• Koyama K, Goto H, Morizumi S, et al. The tyrosine kinase inhibitor TAS-115 attenuates bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol. 2019;60(4):478–487.
   PubMed Web of Science ®Google Scholar
• Doi T, Matsubara N, Kawai A, et al. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2020;38(4):1175–1185.
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Homma S, Ogura T, et al. Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis. Respir Investig. 2023;61(4):498–507.
   PubMed Web of Science ®Google Scholar
• Maher TM, Ford P, Brown KK, et al. Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials. JAMA. 2023;329(18):1567–1578. doi: 10.1001/jama.2023.5355
   PubMed Web of Science ®Google Scholar
• Kraljić K, Jelić D, Žiher D, et al. Benzoxaboroles—Novel Autotaxin Inhibitors. Molecules. 2019;24(19):3419.
   PubMed Web of Science ®Google Scholar
• Sgalla G, Iovene B, Calvello M, et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19(1):32.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Molyneaux PL, Bernardinello N, et al. The role of the lung’s microbiome in the pathogenesis and progression of idiopathic pulmonary fibrosis. Int J Mol Sci. 2019;20(22):5618.
   PubMed Web of Science ®Google Scholar
• Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2(7):548–556.
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Cox MJ, Willis-Owen SAG, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190(8):906–913.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Yow E, Flaherty KR, et al. Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the CleanUP-IPF randomized clinical trial. JAMA. 2021;325(18):1841–1851.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. Journal Of The American College Of Cardiology. 2010;55(18):1915–1922.
   PubMed Web of Science ®Google Scholar
• Whittle BJ, Silverstein AM, Mottola DM, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012;84(1):68–75.
   PubMed Web of Science ®Google Scholar
• Lambers C, Roth M, Jaksch P, et al. Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation. Sci Rep. 2018;8(1):1087.
   PubMedGoogle Scholar
• Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325–334.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med. 2021;9(11):1266–1274. doi: 10.1016/S2213-2600(21)00165-X
   PubMed Web of Science ®Google Scholar
• FibroGen announces topline results from phase 3 ZEPHYRUS-1 study of Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Published 2023.
   Google Scholar
• Jones MG, Andriotis OG, Roberts JJ, et al. Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. Elife. 2018;7: doi: 10.7554/eLife.36354
   Web of Science ®Google Scholar
• Jones MG, Fabre A, Schneider P, et al. Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight. 2016;1(5). doi: 10.1172/jci.insight.86375
   Web of Science ®Google Scholar
• Sgalla G, Wijsenbeek MS, Richeldi L. The shorter, the better: can we improve efficiency of idiopathic pulmonary fibrosis trials? Am J Respir Crit Care Med. 2022;205(8):867–869. doi: 10.1164/rccm.202201-0018ED
   PubMed Web of Science ®Google Scholar
• Khan FA, Stewart I, Moss S, et al. Three-month FVC change: a trial endpoint for idiopathic pulmonary fibrosis based on individual participant data meta-analysis. Am J Respir Crit Care Med. 2022;205(8):936–948.
   PubMed Web of Science ®Google Scholar
• Khor YH, Schulte M, Johannson KA, et al. Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study. Eur Respir J. 2023;61(5):2202163.
   PubMed Web of Science ®Google Scholar
• Adegunsoye A, Freiheit E, White EN, et al. Evaluation of pulmonary fibrosis outcomes by race and ethnicity in US adults. JAMA Netw Open. 2023;6(3):e232427.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093–2101.
   PubMed Web of Science ®Google Scholar
• Oldham JM, Ma S-F, Martinez FJ, et al. TOLLIP, MUC5B, and the response to N-Acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192(12):1475–1482.
   PubMed Web of Science ®Google Scholar
• Podolanczuk AJ, Noth I, Raghu G. Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine. Eur Respir J. 2021;57(1):2003551. doi: 10.1183/13993003.03551-2020
   PubMed Web of Science ®Google Scholar